Shares of enGene Holdings Inc. (ENGN) are down over 65% from their 52-week high of $18.40, recorded in March of this year, and trade around $6.
This clinical-stage biotechnology company is focused on developing genetic medicines based on its proprietary dually derived chitosan, or "DDX", gene delivery platform to improve the lives of patients suffering from bladder cancer. Its lead investigational product is Detalimogene voraplasmid, a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.